Toxic encephalopathy in elderly patients during treatment with capecitabine: Literature review and a case report

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 3, 2011, Pages 288-291

  Fantini, Manuela ^a   Gianni, Lorenzo ^a   Tassinari, Davide ^a   Nicoletti, Stefania ^a   Possenti, Cinzia ^a   Drudi, Fabrizio ^a   Sintini, Michele ^b   Bagli, Laura ^a   Tamburini, Emiliano ^a   Ravaioli, Alberto ^a  

^a Oncology and Oncohematology Department   (Italy)

^b Rimini Hospital   (Italy)

Author keywords

capecitabine; dihydropyrimidine dehydrogenase; fluoropyrimidines; neurotoxicity

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE;

AGED; AMNESIA; ARTICLE; BONE METASTASIS; BRAIN TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CEREBELLAR ATAXIA; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSARTHRIA; ELECTROENCEPHALOGRAM; FEMALE; GENETIC SCREENING; HUMAN; LIMB WEAKNESS; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; MUSCLE HYPOTONIA; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PTOSIS; SLURRED SPEECH; SOMNOLENCE; UNSTEADINESS; VERTIGO;

ADENOCARCINOMA; AGE FACTORS; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FATAL OUTCOME; FEMALE; FLUOROURACIL; HUMANS; NEUROTOXICITY SYNDROMES; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS;

EID: 80053339728     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210374891     Document Type: Article

References (12)

1. Hildebrand J. Neurological complications of cancer chemotherapy. Curr Opin Oncol 2006 ; 18: 321-324. (Pubitemid 44297240)
2. Saif W., Wood TE, McGee PJ and Diasio RB Peripheral neuropathy associated with capecitabine. Anticancer Drugs 2004 ; 15: 776-771.
3. Cavaliere R. and Schiff D. Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep 2006 ; 6: 218-226.
4. Bygrave HA, Geh JI, Jani Y. and Glynne-Jones R. Neurological complications of 5-Fluorouracil chemotherapy: case report and review of the literature. Clin Oncol 1998 ; 10: 334-336. (Pubitemid 28517414)
5. Videnovic A., Semenov I., Chua-Adajar R., Baddi L., Blumenthal DT, Beck AC, et al. Capecitabine-induced Multifocal leukoencephalopathy: a report of five cases. Neurology 2005 ; 65: 1792-1794.
6. Renouf D. and Gill S. Capecitabine-induced cerebellar toxicity. Clin Colorect Cancer 2006 ; 6: 70-71. (Pubitemid 44044005)
7. Couch L., Groteluschen DL, Stewart JA and Mulkerin L. Capecitabine-related neurotoxicity presenting as trismus. Clin Colorect Cancer 2003 ; 3: 121-123. (Pubitemid 37098728)
8. Formica V., Leary A., Cunningham D. and Chua YJ 5-Fluorouracil can cross brain- blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine- induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol 2006 ; 58: 276-278.
9. Niemann B., Rochlitz C., Herrmann R. and Pless M. Toxic encephalopathy induced by capecitabine. Oncology 2004 ; 66: 331-335. (Pubitemid 38822804)
10. Tipples K., Kolluri RB and Raouf S. Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. J Oncol Pharm Practice 2009 ; 15: 237-239.
11. Franco DA and Greenberg HS 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology 2001 ; 56: 110-112. (Pubitemid 32059663)
12. Chansky K., Benedetti J. and Macdonald JS Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005 ; 103: 1165-1171. (Pubitemid 40328086)